Charles Freeman Geschickter was born on 8 January 1901 in Washington, D.C. His father was an inventor and was involved in the fur trade and in cabinet-making.

They identified a number of common features, but not blood protein abnormalities or elevation of the rate of erythrocyte sedimentation.

Geschickter agreed, and before starting work made a tour of pathology laboratories in Europe, including the biochemistry unit run by Otto Heinrich Warburg in Berlin.

[1] In 1931 Geschickter and Copeland, then at the Memorial Hospital for the Treatment of Cancer and Allied Diseases, published a large monograph on bone tumors.

The work, sponsored by the American Cancer Society, was dedicated to Bloodgood, and made use of material that he had collected at Johns Hopkins Hospital.

In an early version of chemotherapy, he successfully used the chemical to remove nickel that had accumulated in toxic levels in a patient's body.

The existing facility would be used for patients who did not require intensive care, while the modern new facility with 21 operating rooms and 192 beds would be designed specifically for the acutely ill.[6] A 1970s Senate investigation of CIA activities found that the CIA had provided funds to Geschickter's private research foundation, which were in turn used for a research building at the Georgetown Medical Center.